[用优福定治疗肝细胞癌——其在与经导管动脉栓塞联合治疗或单次治疗中的疗效临床评估]
[Therapy of hepatocellular carcinoma with UFT--clinical evaluation of its effect in the combination therapy with transcatheter arterial embolization or one shot therapy].
作者信息
Kitamura T, Maruyama T, Nakamura H, Hayashi K, Shigehira M, Iwaki Y, Okamoto T, Ishikawa T, Ishinoda Y, Kisanuki H
机构信息
2nd Dept. of Internal Medicine, Miyazaki Medical College.
出版信息
Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 1):1467-71.
In 55 hepatocellular carcinoma patients treated with transcatheter arterial embolization or one shot therapy, the prognosis of patients treated with UFT (group A; n = 23) were historically compared with those of patients treated without UFT (group B; n=32). In group A, survival rate was 91.3% at 6 month; 67.5% at 1-year, 24.3% at 2-year, 24.3% at 3 year, in group B, 59.4% at 6-month, 37.5% at 1 year, 16.1% at 2-year. In these comparison, group A revealed significantly higher survival rate than group B. These results indicated that UFT was effective as maintenance therapy after transcatheter arterial embolization or one shot therapy with hepatocellular carcinoma.
在55例接受经导管动脉栓塞术或一次性治疗的肝细胞癌患者中，对接受优福定治疗的患者（A组；n = 23）与未接受优福定治疗的患者（B组；n = 32）的预后进行了历史性比较。A组6个月生存率为91.3%；1年时为67.5%，2年时为24.3%，3年时为24.3%，B组6个月时为59.4%，1年时为37.5%，2年时为16.1%。在这些比较中，A组的生存率显著高于B组。这些结果表明，优福定作为肝细胞癌经导管动脉栓塞术或一次性治疗后的维持治疗是有效的。
Zotero 插件